Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
Alkylating agent
DRUG CLASS:
Alkylating agent
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
cyclophosphamide (66)
trabectedin (24)
STAR-001 (16)
lomustine (15)
carmustine (14)
lurbinectedin (11)
melphalan (9)
chlorambucil (7)
melphalan flufenamide (7)
temozolomide gel (7)
procarbazine hydrochloride (4)
OBI-3424 (4)
D19466 (4)
mitomycin (3)
thiotepa (3)
bendamustine RTD (2)
LP-284 (2)
fotemustine (2)
busulfan (2)
VAL-083 (2)
ACHM-025 (1)
BYON4413 (1)
FGX15-147-based ADC (1)
treosulfan (1)
IMGS-101 (1)
bendamustine rapid infusion (0)
ranimustine (0)
carmustine implant (0)
TL-118 (0)
altretamine (0)
mechlorethamine (0)
satraplatin (0)
PR104 (0)
pegylated liposomal mitomycin-c prodrug (0)
QBS72S (0)
mechlorethamine gel (0)
EX-204 (0)
captisol-enabled melphalan (0)
cyclophosphamide intravenous (0)
D 19575 (0)
CB1954 (0)
cyclophosphamide (66)
trabectedin (24)
STAR-001 (16)
lomustine (15)
carmustine (14)
lurbinectedin (11)
melphalan (9)
chlorambucil (7)
melphalan flufenamide (7)
temozolomide gel (7)
procarbazine hydrochloride (4)
OBI-3424 (4)
D19466 (4)
mitomycin (3)
thiotepa (3)
bendamustine RTD (2)
LP-284 (2)
fotemustine (2)
busulfan (2)
VAL-083 (2)
ACHM-025 (1)
BYON4413 (1)
FGX15-147-based ADC (1)
treosulfan (1)
IMGS-101 (1)
bendamustine rapid infusion (0)
ranimustine (0)
carmustine implant (0)
TL-118 (0)
altretamine (0)
mechlorethamine (0)
satraplatin (0)
PR104 (0)
pegylated liposomal mitomycin-c prodrug (0)
QBS72S (0)
mechlorethamine gel (0)
EX-204 (0)
captisol-enabled melphalan (0)
cyclophosphamide intravenous (0)
D 19575 (0)
CB1954 (0)
›
Associations
(203)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Breast Cancer
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive: A1 - Approval
docetaxel + doxorubicin hydrochloride + cyclophosphamide
Sensitive
:
A1
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Retinoblastoma
No biomarker
Retinoblastoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
melphalan
Sensitive: A1 - Approval
melphalan
Sensitive
:
A1
melphalan
Sensitive: A1 - Approval
melphalan
Sensitive
:
A1
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Brain Cancer
No biomarker
Brain Cancer
lomustine
Sensitive: A1 - Approval
lomustine
Sensitive
:
A1
lomustine
Sensitive: A1 - Approval
lomustine
Sensitive
:
A1
No biomarker
Astrocytoma
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Ependymoma
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
prednisone + thalidomide + melphalan
Sensitive: A1 - Approval
prednisone + thalidomide + melphalan
Sensitive
:
A1
prednisone + thalidomide + melphalan
Sensitive: A1 - Approval
prednisone + thalidomide + melphalan
Sensitive
:
A1
No biomarker
Soft Tissue Sarcoma
No biomarker
Soft Tissue Sarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive: A1 - Approval
lurbinectedin
Sensitive
:
A1
lurbinectedin
Sensitive: A1 - Approval
lurbinectedin
Sensitive
:
A1
No biomarker
Chronic Myeloid Leukemia
No biomarker
Chronic Myeloid Leukemia
busulfan
Sensitive: A1 - Approval
busulfan
Sensitive
:
A1
busulfan
Sensitive: A1 - Approval
busulfan
Sensitive
:
A1
No biomarker
Ovarian Cancer
No biomarker
Ovarian Cancer
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
melphalan flufenamide
Sensitive: A1 - Approval
melphalan flufenamide
Sensitive
:
A1
melphalan flufenamide
Sensitive: A1 - Approval
melphalan flufenamide
Sensitive
:
A1
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Liposarcoma
No biomarker
Liposarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Glioma
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
bendamustine RTD
Sensitive: A1 - Approval
bendamustine RTD
Sensitive
:
A1
bendamustine RTD
Sensitive: A1 - Approval
bendamustine RTD
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
bendamustine RTD
Sensitive: A1 - Approval
bendamustine RTD
Sensitive
:
A1
bendamustine RTD
Sensitive: A1 - Approval
bendamustine RTD
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
cyclophosphamide
Sensitive: A1 - Approval
cyclophosphamide
Sensitive
:
A1
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
melphalan
Sensitive: A2 - Guideline
melphalan
Sensitive
:
A2
melphalan
Sensitive: A2 - Guideline
melphalan
Sensitive
:
A2
No biomarker
Peritoneal Cancer
No biomarker
Peritoneal Cancer
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
melphalan
Sensitive: A2 - Guideline
melphalan
Sensitive
:
A2
melphalan
Sensitive: A2 - Guideline
melphalan
Sensitive
:
A2
No biomarker
Fallopian Tube Cancer
No biomarker
Fallopian Tube Cancer
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
cyclophosphamide
Sensitive: A2 - Guideline
cyclophosphamide
Sensitive
:
A2
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
cisplatin + cyclophosphamide + vincristine
Sensitive: A2 - Guideline
cisplatin + cyclophosphamide + vincristine
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login